drugset / Trial / NCT02196701
Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in suboptimal responders to ADA monotherapy.
Timeline
- Start
- 2014-08-05
- Primary completion
- 2017-03-17
- Completion
- 2017-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | Methotrexate | Small molecule | 7.5 mg | Oral |
| Subject | Methotrexate | Small molecule | 25 mg | Oral |